Nouri Keyvan, O'Connell Christopher, Rivas Maria Patricia
Department of Dermatology and Otolaryngology, University of Miami School of Medicine, USA.
J Drugs Dermatol. 2003 Dec;2(6):669-73.
Topical imiquimod is an immune response modifier FDA approved for the treatment of anogenital warts. Recent studies have reported its effectiveness in the treatment of some types of basal cell carcinomas. There have also been some case reports and case series reporting success treating of squamous cell carcinoma in situ with imiquimod. We report two patients with squamous cell carcinoma in situ and one with invasive squamous cell carcinoma treated with 5% imiquimod cream. Lesions were located on shin, posterior shoulder, and nasal tip. 5% imiquimod cream was applied at night for six weeks. Side effects included erythema and crusting in one patient. Biopsies taken four weeks after treatment revealed no residual squamous cell carcinoma in situ or squamous cell carcinoma. Topical 5% imiquimod cream is becoming established as a promising treatment for squamous cell carcinoma in situ. It also seems to be an alternative treatment for some cases of squamous cell carcinoma.
外用咪喹莫特是一种经美国食品药品监督管理局（FDA）批准用于治疗肛门生殖器疣的免疫反应调节剂。最近的研究报告了其在治疗某些类型基底细胞癌方面的有效性。也有一些病例报告和病例系列报道了用咪喹莫特成功治疗原位鳞状细胞癌的情况。我们报告了两名原位鳞状细胞癌患者和一名侵袭性鳞状细胞癌患者，他们接受了5%咪喹莫特乳膏治疗。病变位于小腿、后肩部和鼻尖。每晚涂抹5%咪喹莫特乳膏，持续六周。副作用包括一名患者出现红斑和结痂。治疗四周后进行的活检显示，原位鳞状细胞癌或鳞状细胞癌均无残留。外用5%咪喹莫特乳膏正逐渐成为一种有前景的原位鳞状细胞癌治疗方法。它似乎也是一些鳞状细胞癌病例的替代治疗方法。
